这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Ipilimumab (anti-CTLA-4)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • 反应种属: Cynomolgus,Human,Mouse 
  • 亚型: Human IgG1
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
I411993-1mg
1mg 期货 Stock Image
I411993-5mg
5mg 期货 Stock Image
I411993-10mg
10mg 期货 Stock Image

基本信息

产品名称 Ipilimumab (anti-CTLA-4)
别名 伊匹单抗; 伊匹木单抗; MDX-010; BMS-734016; Yervoy; Ipilimumab; Ipilimumab (anti-CTLA-4); Recombinant Ipilimumab Antibody; Ipilimumab (MDX-010); ALPS5 antibody; CD 152 antibody; CD antibody; CD152 antibody; CD152 antigen antibody; CD152 isoform antibody; Celiac dis
英文别名 MDX-010; BMS-734016; Yervoy; Ipilimumab; Ipilimumab (anti-CTLA-4); Recombinant Ipilimumab Antibody; Ipilimumab (MDX-010); ALPS5 antibody; CD 152 antibody; CD antibody; CD152 antibody; CD152 antigen antibody; CD152 isoform antibody; Celiac disease 3 antibo
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 CTLA-4/CD152
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属 Cynomolgus,Human,Mouse 

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG1
轻链亚型 Kappa
SDS-PAGE 26.9 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 176.3 kDa, under non-reducing conditions.
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 477202-00-9

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al..  (2015)  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma..  N Engl J Med,  372  (21):  (2006-17).  [PMID:25891304]
2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al..  (2015)  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma..  N Engl J Med,  373  (1):  (23-34).  [PMID:26027431]
3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al..  (2018)  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma..  N Engl J Med,  378  (14):  (1277-1290).  [PMID:29562145]

计算器